In general, the available data in Chinese patients with advanced HCC support the use of combination therapy with a PD-1/PD-L1 inhibitor (atezolizumab or sintilimab) and bevacizumab in the first-line setting compared with sorafenib. This evidence concerns the gene CD274 and hepatocellular carcinoma.